OPTION 2 Trial Testing MS1819 for EPI Posts ‘Mixed’ Topline Results

OPTION 2 Trial Testing MS1819 for EPI Posts ‘Mixed’ Topline Results

291288

OPTION 2 Trial Testing MS1819 for EPI Posts ‘Mixed’ Topline Results

Treatment with MS1819 for exocrine pancreatic insufficiency (EPI) — when the pancreas does not release enough digestive enzymes and the body doesn’t receive proper nutrition — was found to be safe and well-tolerated among cystic fibrosis (CF) patients in the OPTION 2 trial, top-line results show. However, MS1819 was not as effective at improving fat absorption as pancreatic enzyme replacement therapy (PERT) for most OPTION 2 participants. This means that the trial’s main efficacy goal…

You must be logged in to read/download the full post.